ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryChâtelaineargenx Switzerland SA
argenx Switzerland SA Logo
Verified· 2 sources

argenx Switzerland SA

Summary

About the company

argenx Switzerland SA is a biopharmaceutical company that discovers, develops and commercializes antibody-based therapies for severe autoimmune diseases. Its portfolio includes the FcRn-targeting agent efgartigimod (marketed as VYVGART and VYVGART Hytrulo), a pipeline of additional antibody candidates such as empasiprubart, and ongoing clinical research.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered
5
Immunology Innovation Program (IIP)
Co-creation in partnership with academic and clinical researchers to transform immunology insights into antibody-based medicines, from discovery through clinical development.
Commercial medicines and products
VYVGART and VYVGART Hytrulo, products approved in the United States, with dedicated information for healthcare professionals and patients.
Clinical development portfolio
Programs for efgartigimod, empasiprubart and other preclinical candidates, phase 1, proof of concept, registrational and commercial across multiple therapeutic areas.
Externally Sponsored Research (ESR)
Support for Investigator-Initiated Studies and Clinical Research Collaboration, with proposal submission, research guidance, and a dedicated point of contact.
Patient access to therapies and clinical trials
Information on clinical trials, pre-approval and post-trial access, as well as resources for patients living with rare autoimmune diseases.

Knowledge

No knowledge articles yet

Once argenx Switzerland SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

argenx Switzerland SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank argenx Switzerland SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of argenx Switzerland SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Place Casa-Bamba 1
1219 Châtelaine

At a glance

Legal form
Corporation
UID
CHE-192.432.916
Founded
2020 · 6 years
Last commercial register change
May 15, 2026
Employees
11 to 20

Similar companies

FG
Fondation Givaudan
Vernier
AP
ARmox Pharma Sàrl
Geneva
IH
IQONE HEALTHCARE SWITZERLAND SA
Versoix
CD
Caisse de pensions Givaudan
Vernier